Neonatal hyper-oxygenation has been demonstrated to produce bronchopulmonary dysplasia. Developing treatments for this syndrome is an unmet medical need. Here at CBI, we have developed and validated robust models for this syndrome, for the purposed of assessing mechanisms of action, and the activity of these treatment modalities. Preclinical models employ neonatal murine species with pups being placed in high oxygen environment for 2 weeks. this induces bronchopulmonary dysplasia and is a useful model of the human disease.

Come see us at SOT this week, where we are presenting a poster on hyper-oxygenation and our proprietary phase contrast analysis- a more reliable and repeatable method than traditional MLI.